title: Phosphodiesterase-III-inhibition with amrinone leads to contracture development in skeletal muscle preparations of malignant hyperthermia susceptible swine.
abstract: OBJECTIVE
  The phosphodiesterase-III (PDE-III) inhibitor enoximone-induced marked contractures in skeletal muscle specimens of malignant hyperthermia (MH) susceptible (MHS) human beings and swine. Whether this is a substance specific effect of enoximone or caused by inhibition of PDE-III remained unclear. Therefore, the effects of the PDE-III inhibitor amrinone in porcine MH normal (MHN) and MHS skeletal muscles were investigated.
  
  
  METHODS
  MH-trigger-free general anaesthesia was performed in eight MHS and eight MHN swine. The MH status of the swine was determined by detection of the Arg615-Cys point mutation on chromosome 6 indicating MH susceptibility. Skeletal muscle specimens were excised for the in vitro contracture tests with amrinone. Amrinone was added cumulatively every 5 min to muscle specimens in order to obtain organ bath concentrations between 20 and 400 micromol L(-1). The in vitro effects of amrinone on muscle contractures and twitches were measured.
  
  
  RESULTS
  Amrinone-induced contractures in all skeletal muscle preparations. MHS muscles developed contractures at significantly lower bath concentrations of amrinone than MHN muscles. Contractures of MHS compared to MHN muscles were significantly larger at bath concentrations of 80, 100, 150, 200 and 400 micromol L(-1) amrinone. Muscle twitches remained unchanged up to and including 200 micromol L(-1) amrinone.
  
  
  CONCLUSIONS
  Inhibition of PDE-III in general elicited higher contractures in MHS than in MHN muscles. Therefore, a contribution of PDE-III and the cyclic adenosine monophosphate (cAMP) system in the pathophysiology of MH must be suspected.
authors.affiliation: University-Hospital Hamburg-Eppendorf, Department of Anaesthesiology, Hamburg, Germany. fiege@uke.uni-hamburg.de
authors.forename: M
authors.initials: M
authors.lastname: Fiege
authors.forename: F
authors.initials: F
authors.lastname: Wappler
authors.forename: R
authors.initials: R
authors.lastname: Weisshorn
authors.forename: M U
authors.initials: MU
authors.lastname: Gerbershagen
authors.forename: K
authors.initials: K
authors.lastname: Kolodzie
authors.forename: J
authors.initials: J
authors.lastname: Schulte am Esch
mesh_terms: D015105:3',5'-Cyclic-AMP Phosphodiesterases / Q000037:antagonists & inhibitors*; D000676:Amrinone / Q000494:pharmacology*; D000768:Anesthesia, General; D000818:Animals; D002118:Calcium / Q000502:physiology; D000242:Cyclic AMP / Q000502:physiology; D054684:Cyclic Nucleotide Phosphodiesterases, Type 3; D003593:Cytoplasm / Q000502:physiology; D005260:Female; D066298:In Vitro Techniques; D008297:Male; D008305:Malignant Hyperthermia / Q000235:genetics / Q000503:physiopathology*; D009119:Muscle Contraction / Q000187:drug effects; D018482:Muscle, Skeletal / Q000187:drug effects*; D010726:Phosphodiesterase Inhibitors / Q000494:pharmacology*; D017354:Point Mutation; D013552:Swine
chemical_list: D010726:Phosphodiesterase Inhibitors; D000242:Cyclic AMP; D015105:3',5'-Cyclic-AMP Phosphodiesterases; D054684:Cyclic Nucleotide Phosphodiesterases, Type 3; D000676:Amrinone; D002118:Calcium